News | April 26, 2024
Merck 1Q 2024 sales up 9% to US$ 15.8 billion
Sales reflect continued strong growth in oncology and vaccines
Sales reflect continued strong growth in oncology and vaccines
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Submission based on results from pivotal phase III trial showing all primary endpoints met
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Submission to be reviewed under FDA real-time oncology review and Project Orbis
HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
Subscribe To Our Newsletter & Stay Updated
